



Correction to: Gout and healthcare utilization and complications after hip arthroplasty: a cohort study using the US National Inpatient Sample (NIS)

Jasvinder A. Singh^{1,2,3,4}  · John D. Cleveland^{2,4}

Published online: 29 July 2019

© International League of Associations for Rheumatology (ILAR) 2019

Correction to: Clinical Rheumatology (2019) 38:1213–1216
<https://doi.org/10.1007/s10067-019-04434-3>

The above article originally published with an error present in Table 1. The data “**Home**” on the first column of the Table 1 should be interchange with the previous data “**Inpatient facility†**”. The corrected Table is shown as follows:

The online version of the original article can be found at <https://doi.org/10.1007/s10067-019-04434-3>

✉ Jasvinder A. Singh
Jasvinder.md@gmail.com

John D. Cleveland
jcleveland@uabmc.edu

- ¹ Medicine Service, VA Medical Center, 700 19th St S, Birmingham, AL 35233, USA
- ² Department of Medicine at School of Medicine, University of Alabama at Birmingham, 1720 Second Ave. South, Birmingham, AL 35294-0022, USA
- ³ Division of Epidemiology, University of Alabama at Birmingham, 1720 Second Ave. South, Birmingham, AL 35294-0022, USA
- ⁴ University of Alabama at Birmingham, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294-0022, USA

Table 1 Demographic and other cohort characteristics

	All Cohort (N= 4116485)*	No Gout (N= 4012387)*	Gout (N= 104098)*
Age, Mean (SE); median	65.2 (0.04); 65.9	65.5 (0.04); 66.0	67.0 (0.09); 67.0
Age category			
<50	449,642 (10.9%)	442,224 (11.0%)	7418 (7.1%)
50-64	1,364,821 (33.2%)	1,330,919 (33.2%)	33,902 (32.6%)
65-79	1,732,014 (42.1%)	1,683,378 (42.0%)	48,636 (46.7%)
≥80	566,521 (13.8%)	552,389 (13.8%)	14,132 (13.6%)
Gender			
Female	2,330,188 (56.6%)	2,303,984 (57.4%)	26,204 (25.2%)
Male	1,776,722 (43.2%)	1,698,847 (42.3%)	77,875 (74.8%)
Race			
White	2,882,040 (70.0%)	2,807,827 (70.0%)	74,213 (71.3%)
Black	225,772 (5.5%)	217,805 (5.4%)	7967 (7.7%)
Hispanic	104,385 (2.5%)	102,364 (2.6%)	2021 (1.9%)
Other/Missing	904,234 (22.0%)	884,338 (22.0%)	19,896 (19.1%)
Primary Diagnosis			
Rheumatoid arthritis	29,173 (0.7%)	28,946 (0.7%)	227 (0.2%)
Avascular necrosis	285,623 (6.9%)	277,134 (6.9%)	8489 (8.2%)
OA	3,447,224 (83.7%)	3,357,983 (83.7%)	89,241 (85.7%)
Other	354,307 (8.6%)	348,167 (8.7%)	6140 (5.9%)
Fracture	117 (0.0%)	117 (0.0%)	0 (0.0%)
Hospital Location/Teaching			
Rural	444,188 (10.8%)	433,750 (10.8%)	10,438 (10.0%)
Urban	1,722,391 (41.8%)	1,680,203 (41.9%)	42,188 (40.5%)
Urban Teaching	1,939,989 (47.1%)	1,888,827 (47.1%)	51,162 (49.1%)
Insurance			
Medicaid	138,809 (3.4%)	136,302 (3.4%)	2507 (2.4%)
Medicare	2,234,674 (54.3%)	2,174,154 (54.2%)	60,520 (58.1%)
Other	102,276 (2.5%)	100,185 (2.5%)	2091 (2.0%)
Private	1,600,829 (38.9%)	1,562,620 (38.9%)	38,209 (36.7%)
Self	32,308 (0.8%)	31,697 (0.8%)	611 (0.6%)
Income Category			
0-25th percentile	653,243 (15.9%)	635,111 (15.8%)	18,132 (17.4%)
25-50th percentile	1,009,677 (24.5%)	984,542 (24.5%)	25,135 (24.1%)
50-75th percentile	1,086,954 (26.4%)	1,059,575 (26.4%)	27,379 (26.3%)
75-100th percentile	1,285,855 (31.2%)	1,254,558 (31.3%)	31,297 (30.1%)
Hospital Bed size			
Small	685,209 (16.6%)	667,201 (16.6%)	18,008 (17.3%)
Medium	1,037,561 (25.2%)	1,010,906 (25.2%)	26,655 (25.6%)
Large	2,383,797 (57.9%)	2,324,673 (57.9%)	59,124 (56.8%)
Hospital Region			
Northeast	818,700 (19.9%)	797,318 (19.9%)	21,382 (20.5%)
Midwest	1,089,883 (26.5%)	1,062,567 (26.5%)	27,316 (26.2%)
South	1,358,856 (33.0%)	1,323,743 (33.0%)	35,113 (33.7%)
West	849,046 (20.6%)	828,759 (20.7%)	20,287 (19.5%)
Annual Hospital THA Volume			
<25	486,120 (11.8%)	472,939 (11.8%)	13,086 (12.5%)
26 to 100	1,461,615 (35.5%)	1,425,450 (35.5%)	25,980 (24.8%)

Table 1 (continued)

	All Cohort (N= 4116485)*	No Gout (N= 4012387)*	Gout (N= 104098)*
101 to 200	1,051,561 (25.5%)	1,025,560 (25.6%)	36,312 (34.7%)
>200	1,117,189 (27.1%)	1,087,744 (27.1%)	29,414 (28.1%)
Deyo-Charlson Score			
0	2,193,575 (53.3%)	2,151,940 (53.6%)	41,635 (40.0%)
1	926,286 (22.5%)	902,768 (22.5%)	23,518 (22.6%)
≥2	996,624 (24.2%)	957,679 (23.9%)	38,945 (37.4%)
Post-THA Healthcare Utilization & In-hospital Complications			
Infection	7592 (0.2%)	7437 (0.2%)	155 (0.1%)
Revision	17,932 (0.4%)	17,552 (0.4%)	380 (0.4%)
Transfusion	937,803 (22.8%)	915,245 (22.8%)	22,558 (21.7%)
Gout	104,098 (2.5%)	–	104,098 (100.0%)
Discharge Status			
Home	2,448,107 (59.5%)	2,386,634 (59.5%)	61,473 (59.1%)
Inpatient facility†	1,649,102 (40.1%)	1,606,861 (40.0%)	42,241 (40.6%)
Length of Stay, Mean (SE); median	3.71 (0.01); 2.74	3.73 (0.01); 2.75	3.67 (0.02); 2.69
Length of Stay category			
≤3	2,499,883 (60.7%)	2,434,036 (60.7%)	65,847 (63.3%)
>3	1,616,602 (39.3%)	1,578,351 (39.3%)	38,251 (36.7%)
Died during hospitalization	8889 (0.2%)	8737 (0.8%)	153 (0.1%)

*U.S. National estimates were based on the following in the 20% NIS sample: All, N=855634; no gout, N=834115; gout, N=21519; N (%), unless specified otherwise

† Inpatient facility included short- or long-term care hospital, skilled nursing facility (SNF), intermediate care facility, or a certified nursing facility

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.